// App-Quantinova.ai

DMT44 : Efficacy in Clinical and MRI Outcomes with Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis (MAGNIFY-MS)

Researchers

Presenter

  • Nicola De Stefano

Principal Investigators

  • Anat Achiron

  • Frederik Barkhof

  • Andrew Chan

  • Tobias Derfuss

  • Suzanne Hodgkinson

  • Letizia Leocani

  • Xavier Montalban

  • Alexandre Prat

  • Klaus Schmierer

  • Finn Sellebjerg

  • Patrick Vermersch

  • Heinz Wiendl

  • Annette Lehn

  • Andrzej Smyk

  • Lidia Gardner

Medical Centers

  • University of Genoa

  • Universite de Montreal,

  • Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona

  • KANSAS UNIVERSITY MEDICAL CENTER

  • University of New South Wales Medicine

  • UCL Institute of Neurology

  • Copenhagen University Hospital, Rigshospitalet,

  • Academic Medical Center

  • CHU Lille, FHU Precise

  • University Hospital and University of Münster

  • Queen Mary University, London, UK

  • Vita-Salute San Raffaele University,

  • Royal London Hospital, Barts Health NHS trust

  • University Hospital Wales

  • The healthcare business of Merck KGaA

Locations

  • Italy

  • Palestine

  • Denmark

  • United Kingdom

  • Canada

  • Turkey

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

  • Dermatology

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • IV

Study Id's

  • NCT03364036

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved